IP Library Granted Patent US 8,097,407
Granted Patent B2
US 8,097,407 · App. 12/321,821 · Granted Jan 17, 2012

Metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression

Assignee: Hansabiomed OU
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,407
App. No.
12/321,821
Granted
Jan 17, 2012
Kind
B2
Abstract

This disclosure characterizes the function and the expression of the human protein encoded by tm9sf4. The protein is highly expressed in malignant tumor cells and therefore is a novel marker for malignancy. Moreover, the protein is involved in the phagocytotic character of tumor cells. This disclosure provides methods and tools to diagnose and follow up malignancy of tumors. Furthermore, means to inhibit phagocytotic character of tumor cells as well as means to treat cancer are provided.

Claims (12)

1. A method to distinguish metastatic tumors from non-metastatic tumors, said method comprising a step of determining presence or absence of expression of SEQ ID NO: 1 in tumor cell, wherein presence of the expression indicates metastatic character of the cell.

2. The method of claim 1 , wherein the presence or absence of expression of SEQ ID NO:1 is determined by using RT-PCR, immunoenzymatic method or in situ hybridization.

3. The method of claim 1 , wherein presence or absence of amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 15 is determined.

4. A method to follow up development of metastatic activity of a tumor, said method comprising a step of determining presence or absence of expression of SEQ ID NO: 1 in tumor cell, wherein presence of the expression indicates metastatic character of the cell.

5. The method of claim 4 , wherein presence of absence of amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO:15 is determined.

6. The method of claim 4 , wherein the tumor is melanoma tumor.

7. A method to detect presence of metastatic tumors in vitro, said method comprising the steps of:

a) providing a kit comprising antibodies capable of recognizing human TUCAP-1 protein by binding to a peptide fragment selected from the groups consisting of amino acid 18-282, 221-235 and 303-352 of SEQ ID NO:1 and a titered positive control comprising a peptide fragment having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:15; and

b) allowing the antibodies recognize TUCAP-protein from tissues and body fluids of patients with tumors,

wherein antibody recognizing TUCAP-protein indicates presence of metastatic tumor character.

8. The method of claim 7 , wherein the tumor is melanoma tumor.

9. A method to detect phagocytic metastatic cells by determining presence or absence of expression of SEQ ID NO: 1 in the cells, wherein the presence of the expression indicates presence of phagocytic metastatic cells.

Assignments (3)
CHANGE OF NAME Recorded Oct 9, 2019
From: EXOSOMICS SIENA S.P.A.
To: EXOSOMICS S.P.A.
Reel/Frame 050675/0252 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2016
From: HANSABIOMED OU
To: EXOSOMICS SIENA S.P.A
Reel/Frame 040510/0963 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2009
From: LOZUPONE, FRANCESCO; FAIS, STEFANO
To: HANSABIOMED OU
Reel/Frame 022424/0287 →
Continuity (2)
Provisional Application 61062453 · Jan 25, 2008
Related Publication 20090191222A1 · Jul 30, 2009